CLEO DIAGNOSTICS LTD

ASX: COV

Sector: Sector:Health Care
Industry group: Industry:Pharmaceuticals, Biotechnology & Life Sciences

Latest COV ASX Announcements

21 Aug 2026 · 2:01 amCompany Administration
Appendix 4G and Corporate Governance Statement
21 Aug 20262:01 amAppendix 4G and Corporate Governance StatementCompany Administration
21 Aug 2026 · 1:52 amFinancial Results
Appendix 4E and 2026 Annual Report
21 Aug 20261:52 amAppendix 4E and 2026 Annual ReportFinancial Results
29 July 2026 · 7:39 pmQuarterly Reports
Quarterly activities and cashflow report
29 July 20267:39 pmQuarterly activities and cashflow reportQuarterly Reports
13 July 2026 · 7:10 pmCompany Update
CLEO Enters Analytical Validation Phase
13 July 20267:10 pmCLEO Enters Analytical Validation PhaseCompany Update
8 July 2026 · 2:41 amDirector Interests
Change in Director's Interest Notice
8 July 20262:41 amChange in Director's Interest NoticeDirector Interests
29 May 2026 · 2:18 amSecurities Administration
Cleansing Notice
29 May 20262:18 amCleansing NoticeSecurities Administration
29 May 2026 · 2:12 amOther
Application for quotation of securities - COV
29 May 20262:12 amApplication for quotation of securities - COVOther
20 May 2026 · 7:25 pmCompany Update
CLEO Establishes U.S. Reimbursement Pathway
20 May 20267:25 pmCLEO Establishes U.S. Reimbursement PathwayCompany Update
29 Apr 2026 · 7:32 pmQuarterly Reports
Quarterly activities and cashflow report
29 Apr 20267:32 pmQuarterly activities and cashflow reportQuarterly Reports
28 Apr 2026 · 6:26 pmCompany Update
CLEO Commences Kit Manufacturing Ahead of FDA Submission
28 Apr 20266:26 pmCLEO Commences Kit Manufacturing Ahead of FDA SubmissionCompany Update
31 Mar 2026 · 8:04 pmCompany Update
Sample Collection Completion for Pivotal US Clinical Trial
31 Mar 20268:04 pmSample Collection Completion for Pivotal US Clinical TrialCompany Update
23 Mar 2026 · 7:29 pmCompany Update
CLEO Optimises Biomarker Panel Ahead of FDA Submission
23 Mar 20267:29 pmCLEO Optimises Biomarker Panel Ahead of FDA SubmissionCompany Update
26 Feb 2026 · 3:24 amFinancial Results
Appendix 4D and Half Yearly Accounts
26 Feb 20263:24 amAppendix 4D and Half Yearly AccountsFinancial Results
18 Feb 2026 · 8:44 pmCompany Update
CLEO Confirms Next-Gen Platform for Ovarian Cancer Test
18 Feb 20268:44 pmCLEO Confirms Next-Gen Platform for Ovarian Cancer TestCompany Update
29 Jan 2026 · 7:24 pmQuarterly Reports
Quarterly activities and cashflow report
29 Jan 20267:24 pmQuarterly activities and cashflow reportQuarterly Reports

View complete COV announcement history →